CYRX - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. And welcome to the Cryoport’s Second Quarter 2022 Earnings Conference Call. All participants will start in a listen-only mode. [Operator Instructions] As a reminder, this call is being recorded. I will turn the call over to your host Todd Fromer from KCSA Strategic Communications. ahead. go Please

Todd Fromer

operator. Thank you,

that begin currently statements that today, All to we and not forward-looking or would that in and anticipate the assumptions future to based I conference call on our everyone are management developments events this performance, statements. These our remind expect contains team. or address occurring available forward-looking Before statements. operating like information we are certain statements beliefs on forward-looking management's

these forward-looking made. that are reasonable Our when believes management statements as and team

a statements However, undertake on future or you when should any publicly statements, law. such not otherwise, result or not required only events as by revise place obligation any undue forward-looking of as reliance statements, as or new because speak do forward-looking update date information the of except to made. We any such whether

the Cryoport. from Officer Report Securities reports, call Executive to filed Exchange floor XX-K pleasure turn with those subject our described my are actual Commission. Chief to It materially risks statements XA, not and experience results, forward-looking described Exchange those or include, the our Mr. Shelton, of and limited and but the to and Risk over and are Item uncertainties uncertainties on cause from we is and filed developments Annual events time-to-time addition, Form to elsewhere to Commission, differ in other projections. These and present that the historical the could Jerrell Factors in Securities which risks Jerry, with in yours. certain In expectations is our now and

Jerrell Shelton

Vice afternoon, Chief Scientific of today. us joining Corporate and Mr. Stefanovich; Financial ladies Relations, this Mark our Good afternoon Investor Development President Chief gentlemen. and you, you call our Heinzen. We With Dr. and our our Thomas Officer, Robert Sawicki; is Officer, earnings Thank appreciate Todd.

Relations financial operational in have document outlook. review It reminder, section. Presentations" be the quarter a Investor This uploaded our and XXXX general website. "Events our provides the can and review recent found performance document a business to under and second we a As in of

your If provide business, you encourage read will update have to you download a on I not had chance I then our it, brief million. answering would website we'll it. strong business move on questions. our to to and units increasing and on go a XX% geographies second to all revenue solid Reflecting delivered and quarter to another a across demand basis record constant quarter $XX.X XX% a or currency we with

period. our double all this Importantly, line in delivered business growth digits, top

continue basis XXXX increased from more operations XXX Our production. Prague approach manufacturing to New quarter gross margin as first discipline points to than as return slightly we at CapEx our our

products Although the volatile macro services remain demand for and been this year environment has our strong.

through expansion of quarter was opening business are supply We global continued for projected both first and demand projects. two to Jersey this meeting expansion report milestone foundation and demand the important located centers. us of clients. These chain acquisitions for Global Supply form our facilities happy Network. and staffed Center of An internal through fully are preparing facilities world-class Chain our during in that accepting and the and two Texas, Morris New our Plains, the I'm Houston, both are new

further France. of Cell&Co strength quarter, acquisition located as the also the we the the with Clermont-Ferrand, front, on EMEA were During acquisition presence busy we region our BioServices in in

EMEA approximately region years. an Cell&Co role and expands accelerating important and by our processing. of in in Sciences' located apheresis platform cryo-preservation, cryo-process, standardized upstream capabilities, further by our closed its in optimization, support on Global Belgium. just the last Cell the Center Supply acquisition licensing company which Life our expansion of from and specializes of will week Cell strategic two Liège, Chain chain Network play for Given collection Also locations, we the new in supply cryo-processing, the Matters Matters,

Our moving Across new a Life forward global we delivering continually are footprint increasing coupled solutions efficacy need. increasingly is and gene markets systems, to our and providing processes and the expanding achieving cell in as products, the new growing for and Sciences. services, for essentiality industry us with patients of portfolio within our de-risk therapy

which development, capitalize as have that our alliances. clients. through deepen platform and been We we our to believe global looking opportunities relationship successfully in this and accomplished business there methodical still we and many footprint And disciplined have expanding ahead, our we partnerships, on can with organic is acquisitions,

which in plan a we're to medicine our is Regenerative position is initiatives. Fortunately, financial support strong growing. $XXX cash, growth sufficient in million approximately with

from And regenerative reaching end a in of a the Cryoport of trials, year. over pipeline noting is Phase a worth total record so XX, clinical trials by time same over a year with of quarter increase second of these XX customers XXXX our that and XX is up at quarter medicine of XXXX, are in XX second supporting last the It this in. the of number of XXX X, record net potential, global commercial

services In services, from systems commercial therapy Therefore, includes fulfillment. our expanding labeling, will strong which we revenue demand to and by for increased addition ends new solid client kitting, bio my benefit This demand and our guidance and and utilization XX% current $XXX our a also are remarks. of full confirming product, across to to year that to storage, represents units. are business million growth This XXXX guidance $XXX XX% prepared driven is revenue secondary million.

your happy to take Now we'll be questions.

lines operator, you'll please questions. open the So if for

Operator

now the go SVB question-and-answer come And We will [Operator Souda question Please of session. will Puneet ahead. begin our Instructions] first Securities. from

Unidentified Analyst

taking have for you question. Michael Yes, thanks Puneet. Yes, my on Hi. for

margins? for your of of my overall, So spread are any give on is the and could I line impacting on what do that impact how parts meaningfully XXXX wondering you then impact impact business. top first in see you color FX contemplating the FX was just the across various question, you And for for quarter, the FX any

Jerrell Shelton

Michael. the question, for thanks Yes,

on Just a few comments that.

the our earnings seen you did kind growth. As reported currency the versus as of revenue disclose have in we constant release

reported So currency, as and XX% XX%. constant

We XX% of our have roughly about – to is related foreign about revenue currency.

$XX.X Without $XX.X QX. million. saw impact, million So an been the would've that revenues, in of we impact instead certainly

So about basis. a on in revenues increase constant currency $X.X million

So exactly we nobody forward expect Obviously, there is the of going exchange rates half where knows to see the be. impact year. the into do an impact second will

In animal terms of in on seen various markets, the we've and impact three the obviously all really in biggest exchange part, on rate on impact the being an biopharma. health markets

Unidentified Analyst

I question then And helpful. That's trials. it. a about clinical think Got

see, especially just And from if are these is pharma? is how versus it of big smaller there many biotechs? it's across or all guess, and we're the and potential on net servicing with to cancellations small the any possible curtailing, color macro trials you good are So given wondering, environment, to biotechs ads just give I clinical board just any

Jerrell Shelton

to Yes, programs we entities support no that cash the supported we support within an and in very evidence We've position. see we analysis any portfolio clinical are deceleration of the that a the internally from activity done it as relates date. well to programs

macro And negative have a high degree confidence impact of we see going any so of sort any to not that related environment. we're to

and overall. into cell is a the still and In There healthcare biotech very of going being relates invested. to fact, still lot space investments is gene as it robustly space the

Unidentified Analyst

Thank very much. helpful. Great. That's you

Jerrell Shelton

Thank you.

Operator

question comes of John UBS. The next Please Sourbeer from go ahead.

John Sourbeer

year-over-year. you color just the continue ramping the to XXXX? you in Maybe taking question for the of for way question. guidance commercial half see on the what on on Any revenues, a second throughout and the how ramp provide thanks Hi, to some outlook have year that my

Robert Stefanovich

the revenue of it a of see outlook, the on before of the revenue guidance reiterate driven maybe it, well. We clinical comments year growth and to and commercial full revenues. million. ultimately in growth I units that and granularity and revenue we by guidance $XXX business well. on for the as Mark is We now just going provide as trials, of Yes, then mix that give the don't do be the the maturation did

Mark Sawicki

commercial We to we're nine and a just couple behind can. programs. reasoning building the areas a and cell had where there that still robust continue, that, we've despite clinical in to That's to early supporting to trial gene anticipate transition growth into its of that different as of the a therapies Yes, is as add demonstrated pipeline focus currently significant has we ability do And and obviously is that. development. fact very commercial on

continued pushing And that second moving seeing success approved on lot therapy So success therapies are And and treatment. of even in number is, on therapies launches. geographies. seeing we're any new on which line the line expansion to include have line and focused from are lot global basis line also therapy launching first third new of a indications now supporting expanding these them line also we're that A now. third of and the we're towards earlier in also foremost seen substantial to a countries and of fourth therapies from new doesn't they really

So the growth of I and very for to is this combination four these a drive positive in things continue will us. element think space

John Sourbeer

follow-up appreciate what are add anticipating last comments a Got it. color are just opportunities just allogeneic you additional color. some the on can XXXX? see you And in On allogeneic? the maybe approvals on therapies, I there. the any And around you

Jerrell Shelton

Tom, why that? don't you take

Tom Heinzen

at pipeline two And of you than bit Hi, year. little supporting allos maybe a we're John point. could allos, three our this be recall, there more currently approved if XX% allo this is

John Sourbeer

one appreciate Prague last I on additional that New It you And and then business? it. color. provide can is just one. MVE the how sounds looking into color I like at any is the recovering maybe facility on guess maybe insight operational is backlog Got capacity. Any that the how

Jerrell Shelton

in production this the the that rest plant working Yes, throughout working is first year of up loss and at is had the lost MVE doing MVE quarter. to hard is well had, the we we doing very capacity the fine We're well. the But point. make

John Sourbeer

Great. taking the and my questions. Thanks for color

Jerrell Shelton

you. Thank

Robert Stefanovich

John. Thanks,

Operator

Baldry Capital. next question of Richard comes from Please ahead. go The Roth

Richard Baldry

the is controls, curious your gating is the question This commercial I what I'm think but growth sort think I So at for of of you the rates me of own side the what outside business? the critical I indications faster. growing providing, treatment sort XX%. significantly are that seems protocols It is to online, would read have of be new that thought would number of they that coming Thanks.

that's how do you Thanks. over think there manufacturing it's back term? otherwise and that intermediate near, will capacities, that is the of sort So holding whether progress something,

Tom Heinzen

is swing days Myers capacity. out you can it first if Mark a capacity they XX%, reported by at but at at increased capacity on again. their new as that's hit Thankfully a ago in here, Bristol of head, go it's facility tilt. have it's increase their to And it fully lot it then called take full They Rich, and did more on Tom, they ahead that couple we look of and up opened back a add you the just a ours demand, not out. maybe and demand. then customers coming running Gilead couldn't it. their that fill up I'll But hopefully speak Again, Hey, manufacturing we Maryland quarter building

biggest So today. that's the Mark? thing

Mark Sawicki

hit the final product No, And two vector are capacity. them. mentioned of you down in I I Tom mean, there manufacturing it Maryland online. starting second these are one lot capacity, on primary And Frederick, of is think is bringing viral of production. internalize folks Kite a the viral the companies vector is One a right lot to issues. facility head. which is

supply more a to over their chain So scalability. that they barrier control and eliminate as have

Richard Baldry

third on hands to acquisition a would maybe most deals? way there the in talk revenue the back not were, maybe fourth Thanks. into you get any of little if quarter have brought own? of and qualitatively bit, from could the around some your kind recent size to quantitatively how or impacts our entities and the Is concepts in And those those large our that headcounts qualitatively

Jerrell Shelton

they acquisitions. strategic if acquisitions at a those Yes. you to as broader in terms about we but a the they Matters, And initiative. component part we to end revenues I of small you acquisitions, start going it's at certainly those of size strategic ultimately, them, talked that if relatively mean, closed all that very are We small acquisition. look look you have acquisition, Cell this but quarter are subsequent look at to say generating

market. at You an of that's out. earn Express in million $X.X of Polar look Spanish the Spain part was the with into expansion acquisition That CRYOPDP an

revenue. So those some contribute to going are

closed which acquisition over than If contribution, have April a selling you in look we the France, a that at million, they was $X little less Cell&Co, $XXX,XXX. in

Robert Stefanovich

the For quarter.

Jerrell Shelton

yes. quarter, the For

Richard Baldry

Thanks. Great.

Jerrell Shelton

rich. Thanks

Operator

from comes please Riley question next Securities, The of B. Yuan ahead. Zhi go

Yuan Zhi

on an impressive team. Hi quarter. Congratulations

and the Cryoport So maybe Systems directly see Jerrell. When question CRYOPDP. we look locations between first began and to some we overlap global at to footprint

replicated here? couple either plan the the segments So you maybe, between you talk plan the success numerous last can EU U.S. have the the EU in synergy the to acquisition the months, or about in improve to happened you U.S. two do here, here in these considering

Jerrell Shelton

Systems absolutely will time. mission serving no biopharmaceutical, specialty Cryoport which a There but carrier the on than is working really and overlap. we are has we different improve CRYOPDP, a them over synergies is

Mark Sawicki

thing I'll obviously associated makes add at and facilities, sense other that focused with The associated synergies business that is where as are common looking management platform. it opportunities for well just as cost with we to for co-location co-occupying on the

at So also synergy are activity. both factors of things that those in looking significant

Yuan Zhi

existing are the an That's these Yes, the is a improvement metrics And it. helpful. customers customers? curious, to half or mentioned interesting from from audit, quarterly is here compared first got some And you of there here, follow-up review, new XXXX? quality just

Mark Sawicki

of it pipeline growing time business. all mix new but grows because we existing, of keep the a It's and our

we was quality We anything. our quality we for see disclosed was something lot, reports our important. at are Streets, these dedicated that our how team, talk systems, globally we to about quality but the customers, really processes. thought to it's everyone looks thought we So important hadn't it And a our

Yuan Zhi

Gilead question you last supply is improvement XXXX, reiterate and just us, culture guidance started to on expectations, one you guys And curious the some cell gene of like for announced. the the since and book therapy see great have based the again a in order Thanks. your since from Yes. we chain and mentioned, calculated had guidance just

check we any read that to to the is about if through near modeling. when book the we there term have, and order want demand think your Just

Jerrell Shelton

Yes, chain I we're about that we revenue if mean, supply you can year. the we look issues, foreign full exchange, the just obviously feel the for guidance, at very looking achieve and clearly the still the at strong

you guidance. to reiterating I if So, anything. hence don't we’re add that want Mark, know,

Mark Sawicki

only thing Yes, you asked is, the add I'll order about book.

extrapolations we relates get we to it our do as we service based considerations on forecasting And as obviously client in clients feedback. information our as from so, And much try volume business. to can our around particular,

right step account amount MAA And further BLA well. filings into we do the we XXX to you so that to, we're that a that have are those now at clinical and where supporting of And back look as will filings, contribute take and as are again, being trials expected company, the dynamics.

of clinical strong the will kind of ultimately trial assist for very strong portfolios a have the a in we revenue that remainder So customer driving base, support the of year.

Yuan Zhi

Great. Thank you for the additional contact.

Jerrell Shelton

Thank you.

Operator

David from ahead. of please Needham comes question next Saxon The & Co. go

David Saxon

for the $X.X but Thanks does everyone. questions. million the the congrats guidance from this Hi a acceleration sort And Yes. revenue also into require back some question. fire. you of last have Yes, Maybe taking half, the the quarter. on of to follow-up

you of And the to $X.X that – million? wanted cadence were of that to for in second did just So quarter? is the see you left the recapturing able expectation recapture whatever what's

Robert Stefanovich

question. very a good no, it's Yes,

be revenue to growth for the if not our This start units of is from is driven the driven very in of this QX, seeing Prague by very just really performance clear, facility. at recapture all I where solid by think New growth. you look business

Biological So three recapturing, as of Solutions. MVE the revenue we time, in that's of going in manufacturing brought of is the which QX, terms Prague, to as mentioned, one New we facilities happen manufacturing from facility over

recapture As some serve going the that has base to of ramped over up, quarters. the obviously client we're revenue and that

the by So collectively. growth of really business all is QX really the on impact is our minimal, units driven

David Saxon

Okay.

extend hearing I'm correctly, XXXX. correct? into that that might So, Is if it

Robert Stefanovich

in with and so, demand. we And at by are really QX up I Prague the had Certainly revenue, it's look say New revenue I – from facility exact we the an revenue, recapturing you are and on think No, of some as right? the you well. that's issue that's we that through I fire can't that look fully bringing damage. science, but quantify running, mean, When being the not And client at driven really recapturing more. when

Jerrell Shelton

order third didn't that we a David, to added catch in we before. shift up have

So, can year. this catch think we up we

David Saxon

question from just you perspective? margins, an margin, then all so take offsetting to whether And you Thanks see, my then much. Okay. Got that? is to on And some wondering, price is can not inflation just gross or improvement, there was it. what good which of seeing sequential second at are

Robert Stefanovich

Yes, to over time. look, gradually have you had are expect we a strong, do those absolutely over right growth margins sequential QX. gross we and We really margins strong, stabilized improve believe

at look investments of are to the we the You types in we're making seeing growth have also expected that market. this and

margins gross impact is bio services. example will that So

facilities bio processes Houston in So in services. two Plains services bio and Clients through up as going had Morris come through, were We June. we're in just those wrap seeing through are the to start you will opened now well. in revenue facilities that and starting audit

gross expect, I'd So margins to improve.

the pricing, most – the of made exchange that's review well at terms pricing In foreign as exercise an looking we our currency. have we and really like looking to adjustments adjusting pricing, our where trends we pricing, at ongoing companies are looking inflationary as as our

David Saxon

you. Thank it. Got

Operator

The comes from Brandon next Couillard Please ahead. of question Jefferies. go

Unidentified Analyst

Hey Brandon. the on Thanks guys, for is this Matt taking for question.

learned [indiscernible] expect talk guys you portfolio Cell acquire impact little of about deal to on all kind how cryo-preservation Maybe week, bit You the expand did this the from ability a going the Matters maybe bit to this year? your you it enter asset about offering into then offers strategic more? do one was can a partnership planned? you you forward? to talk First, them with And the upstream a partnership what this if you

Jerrell Shelton

we're consideration activities well is processing the and that associated upstream. industry the one to product, got of of is all the product pain for critically apheresis last doing chain distribution leukapheresis pain initial industry and engagement gene that. addressed. the will overall to resounding biggest substantial critical to around the a related always deficiency moving is in the in it collection a general. pain point This needs requirements world. one this the years. and us the platform, of quality gives critical activities And as based of product point the things provides a and it collection as cell collection been as related supply the be And And seeing this variability always point that companies address We've moving are these of so Yes, of in distribution. around the a it's address lot feedback opportunity on feedback And we're is fresh also a from But number the evaluating well de-risk that as improve manufacturing the ability particular that activities. to with processing and which in marketplace is related

think product from to And feedback the that's de-risk, significant we going obviously that an improves opportunity it's it's overall it's quality So an platform we're a And opportunity that the well. the centers. as manufacturing a industry into to present that's substantially the opportunity. getting

Unidentified Analyst

kind that facilities once [indiscernible] year? we XX [indiscernible] to [indiscernible] those you you your from thoughts how and potential through is another of talk out two there revenue a utilization facilities the look or new normalized of XX just opened, if expect timing operations. way on to base? the reactions – you question handicap to initial back And sorry, customer [indiscernible] guys the their two noted going handful more months that can that, of And then are just kind about think audit following-up to then there Robert at I new

Mark Sawicki

Yes.

clinical locations. So already We're supporting activity client there in both already client activity. is

through already we've So it's – not the gone process.

being our and with to be with audit quickly can. online storage area backlog takes that as And as related out said, pre-completion we're in the associated bringing services services the time service product clients build in there we the to facilities obviously considerations. of fulfillment componentry it still actually certain to able That Some them. move bio

go the through So have because all instantaneously regulatory at operating, processes. are now you to services

of it's XX-month So, to a storage from XX- a probably assets from full that perspective, get absorption you those process our before particular consideration. of a

Jerrell Shelton

and if you ALLO ALLO keep one any mind ALLO ALLO coming market, Matt, think to aren't thing and in to there is about getting yet. approved other approved

to their else. have be they they be this to clients’ can into we everything our can our So getting demand in as filings, facilities be and curve in of so be ahead auditing the

big too the So be bit. have a we global of moving services, to the us bullish to But network. this supply of We the on forward. ahead. we're far chain It's whole for a ahead factor want out don't really bio going be network to be

David Saxon

I'll leave there. you Makes guys. sense. Thank it

Jerrell Shelton

Thank you.

Operator

Please comes next from ahead. The BTIG. David of question go Larsen

David Larsen

that Hi, to how correct? what and FX was how semiconductors, like drag. coming quickly or I delay? just Thanks. a costs steel, are you a react me, quickly And can remind then impact? inflation quarter pressures the those and So turn that think you price a is see you freight if month million was actually delay said revenue through? around you increase then can or do And same with it six-month like higher can Is $X.X you like you seeing price? there

Robert Stefanovich

Yes, absolutely. no,

FX So the is for for six it’s terms million, quarter of the about about the just months in $X.X million. $X.X impact,

been record impact, impact, still higher. we rate would've it showing quarter, have have quite obviously an it if did the us bit of a So revenue for in spite second exchange didn't an

QX of the well. a is In time lag act, can the that's as between time trends, supply we changes, chain something have issues already terms that that’s balancing done there and the pricing during implement inflationary we which certainly or

see so place. arrangements in of be And you the will have in to some they kick those contractual put

typically, see than that it there. you more be a lag will month will So time

David Larsen

of my it's New at on this of level three sort Prague three Is, demand. then each is for capacity, meet shifts all And of Okay. full that high plants that MVE, at and and correct? them of them have facility is is to case? up is understanding triple there in that's the the And operational going

Jerrell Shelton

our operations. three don't has comment on facility We The details New about shifts. Prague normally

But of full New at operations capacity operating the Prague as an the fire. are other because well. was exception

David Larsen

just competitive relationship last investors may then they BioLife, been from my any Like question, the example, I've Fisher. think, getting And for market. Thermo around thoughts on with questions like I Okay. have a

Just any a on environment. thoughts Thank broad you. competitive

Jerrell Shelton

Yes, a or competing your customers, are your of And David, entities often this with are co-opetition. you is market are that suppliers.

nature of the that's so, the market. And

terms said can competition and And all And are over In market competition and market But we market are I've the leaders small over, the it's expect of as on we're market it a market growing. to remain competitors. fronts and and be we they is growing the the we grows. definitely leaders, committed to continuing leaders.

David Larsen

great. much. Okay, very Thanks

Jerrell Shelton

Thank you.

Operator

our question comes from Instructions] And go Jacob Please Stephens. Johnson [Operator ahead. next of

Jacob Johnson

thanks. a guess and things. centers Hey, supply couple Matt's opportunity on about just first, follow-ups couple I Good a afternoon. the chain thinking the question on there. different follow-up about Maybe

guys a of million there commercial what opportunity? this the for from way million to that supply $XX revenue tease Is out have target $X kind centers to of represent therapy. any You of chain

Jerrell Shelton

our don't we of details on Jake, operation. comment

making, are to significant facility, our out, that were chain and into have been are years product – the customers running they are already moving their thought well clients already into into coming they So, centers up strategy three supply these the facility. and

as about supply a you Jacob, with that are these to two I And can global tell supply are network. significant. going chain to be as they of that's centers first chain the go except that So far

that more you discussing in see lot four have We can right a that expect now. to more And we're area. activity

Tom Heinzen

you have driving driving every of expansion Basically, platform acquisition around at existing Jacob out of through the and revenue strategies of each core look focused obviously organization. on that that. that, and to within one patient patient really a is is that of services diversification percentage thing through relationships our interaction basis revenue and Yes, per new the if we I'll we of our get our service only is add

Jacob Johnson

of guidance I seen Okay. today. gave a of of pick headwind, are figured kind give on of your I have for to maybe mean, since on kind And offsetting some your shot. that. so headwinds I brain through Robert, FX or just we've you kind increasing as you but headwind, FX larger and is expectations FX there operationally just intensified read of I wanted some guidance, M&A it would you that you we that's kind reiterated should then there flowing it Thanks initially that. a the

Robert Stefanovich

immersed think, at, look, very base I and looking that into as the covering and companies, client we And mentioned at the clearly trials. we're So lot Mark, gene forecasting and we're and space, have. therapy our I mean, a cell with of information looking clinical portfolios really

strong the market courier having discussions trials, being So we that, of MVE with systems. the CRYOPDP, And temperature-controlled the the with if our related solutions. we're have for in shipper you impacts for have risks, chain foreign presence the revenue feel with year. supporting It's risk our the in visibility. see clients. guidance space and clinical based leader that how we lot the And to confident again, now, you'll said exchange at obviously, positioning on look guidance. And freezers strong in full the couriers, that queue, leadership see to and cryogenic views a we're that year that right [indiscernible] very supply and translations, we our we global especially others. the have factors that Having with trying weigh And revenue and we give a

So full a we that that have contributed of guidance. number revenue year streams all to

Jacob Johnson

for I'll Thanks. there. Thanks leave Robert. that, it Okay.

Robert Stefanovich

you. Thank

Jerrell Shelton

Thank you.

Operator

conference turn Jerrell would the session. over any to This back concludes to closing our like remarks. for question-and-answer I Shelton

Jerrell Shelton

life industry, operator. supporting supply our In animal demonstrating our the leadership for control, enabling spectrum. hard medicine, temperature life to you especially sciences. health be comprehensive, quarter markets sciences clinical in successful, you, reproductive quarter and another solutions the and the closing and XXXX fully position chain integrated, biopharma, life-saving Thank commercially had of was, We're commercial cell therapies gene working world's the to across the and most first company

the biotechnology of we today. us innovation, on on progress is We to platform and essentiality and We of interest markets. next company. the to the is their continue quarter. from growing achieve stages you research in commodities a will delivery earlier integrated our end industry agility, the updating evening. and industry leadership, your form. focus final reliability, good supply forward Our look to excellence to strive providing dependability, a Thank for you have fully appreciate support Cryoport chain to We again, continuing our joining our for in and a you known hope

Operator

attending now may The conference now disconnect. you Thank for presentation. concluded. you today's And is

Cryoport (CYRX) 6 Aug 222022 Q2 Earnings call transcript